| Literature DB >> 25404001 |
Sukhontip Klahan1, Chun-Nan Kuo2,3, Shu-Chen Chien4,5, Yea-Wen Lin6, Chun-Yi Lin7, Chia-Hsien Lin8, Wei-Chiao Chang9,10,11,12, Ching-I Lin13, Kuo-Sheng Hung14,15,16, Wei-Pin Chang17.
Abstract
BACKGROUND: Osteopontin (OPN) is a pro-inflammatory cytokine which is expressed in various tissues. It participates in the bone remodeling process and stimulates bone resorption by osteoclasts. It is also a core protein of cholesterol gallstones. We hypothesized osteoporotic patients might have higher risk in developing gallstones and conducted a population-based study to examine the risk of developing gallstone in osteoporotic patients in Taiwan.Entities:
Mesh:
Year: 2014 PMID: 25404001 PMCID: PMC4247648 DOI: 10.1186/s12876-014-0192-z
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Demographic characteristics and comorbidities for the osteoporosis and comparison cohorts from 2003 to 2005 ( =8190)
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
| 1 | ||||
| Male | 242 | 14.8 | 968 | 14.8 | |
| Female | 1396 | 85.2 | 5584 | 85.2 | |
|
| 1 | ||||
| 50–64 | 648 | 39.6 | 2592 | 39.6 | |
| 65–79 | 808 | 49.3 | 3232 | 49.3 | |
| ≥ 80 | 182 | 11.1 | 728 | 11.1 | |
|
| < .001 | ||||
| 4.76 | 0.97 | 4.88 | 0.66 | ||
|
| 0.037 | ||||
| 1 (most urbanized) | 443 | 27.0 | 2010 | 30.7 | |
| 2 | 452 | 27.6 | 1688 | 25.8 | |
| 3 | 229 | 14.0 | 929 | 14.2 | |
| 4 | 264 | 16.1 | 1035 | 15.8 | |
| 5 (least urbanized) | 250 | 15.3 | 890 | 13.6 | |
|
| 0.006 | ||||
| 0 | 567 | 34.6 | 2520 | 38.5 | |
| NT$ 1–15,840 | 245 | 15.0 | 809 | 12.3 | |
| NT$ 15,841–25,000 | 695 | 42.4 | 2724 | 41.6 | |
| NT$ ≥25,001 | 131 | 8.0 | 499 | 7.6 | |
|
| < .001 | ||||
| Northern | 687 | 41.9 | 2953 | 45.1 | |
| Central | 467 | 28.5 | 1630 | 24.9 | |
| Southern | 355 | 21.7 | 1566 | 23.9 | |
| Eastern | 129 | 7.9 | 403 | 6.2 | |
|
| < .001 | ||||
| Yes | 1212 | 74.0 | 4548 | 69.4 | |
| No | 426 | 26.0 | 2004 | 30.6 | |
|
| < .001 | ||||
| Yes | 895 | 54.6 | 2914 | 44.5 | |
| No | 743 | 45.4 | 3638 | 55.5 | |
|
| 0.008 | ||||
| Yes | 658 | 40.2 | 2399 | 36.6 | |
| No | 980 | 59.8 | 4153 | 63.4 | |
|
| < .001 | ||||
| Yes | 368 | 22.5 | 900 | 13.7 | |
| No | 1270 | 77.5 | 5652 | 86.3 | |
|
| 0.773 | ||||
| Yes | 2 | 0.1 | 10 | 0.2 | |
| No | 1636 | 99.9 | 6542 | 99.8 | |
|
| <.001 | ||||
| Yes | 99 | 6.0 | 17 | 0.3 | |
| No | 1539 | 94.0 | 6535 | 99.7 | |
|
| 0.826 | ||||
| Yes | 10 | 0.6 | 37 | 0.6 | |
| No | 1628 | 99.4 | 6515 | 99.4 | |
|
| <.001 | ||||
| Yes | 231 | 14.1 | 298 | 4.5 | |
| No | 1407 | 85.9 | 6254 | 95.5 | |
|
| 0.813 | ||||
| Yes | 4 | 0.2 | 14 | 0.2 | |
| No | 1634 | 99.8 | 6538 | 99.8 | |
|
| 0.045 | ||||
| Yes | 1 | 0.1 | Na | Na | |
| No | 1637 | 99.9 | 6552 | 100.0 | |
|
| 0.724 | ||||
| Yes | 2 | 0.1 | 6 | 0.1 | |
| No | 1636 | 99.9 | 6546 | 99.9 | |
|
| 0.070 | ||||
| Yes | 1 | 0.1 | 21 | 0.3 | |
| No | 1637 | 99.9 | 6531 | 99.7 | |
Incidence of gallstone among the osteoporosis and comparison patients from 2003 to 2005 ( =8190)
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| 5-year follow-up period | ||||||
| Yes | 425 | 5.2 | 114 | 7.0 | 311 | 4.7 |
| No | 7765 | 94.8 | 1524 | 93.0 | 6241 | 95.3 |
| Crude HR (95% CI) | 1.50 (1.21 - 1.86)* | 1 | ||||
| Adjusted HR (95% CI) | 1.35 (1.07 - 1.69)** | 1 | ||||
*p <0.001, **p <0.05.
Both crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional-hazard regressions stratified by age and sex.
Adjustments are made for sex, age, patients’ monthly income, region, urbanization level, hypertension, hyperlipidemia, diabetes, cirrhosis, spinal cord injury, hormone replacement, and clofibrate.
Figure 1Gallstone event-free survival rates for subjects with osteoporosis and the comparison group from 2003 to 2005.
Overall and age- and sex-specific incidence densities and relative hazard of gallstone in the osteoporosis and comparison cohorts
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |||
| Age (y)a | ||||||||||
| 50-64 | 42 | 3080.05 | 13.64 | 9.54 - 17.73 | 103 | 12702.40 | 8.11 | 6.55 - 9.67 | 1.68 (1.17 - 2.40)** | 1.56 (1.06 - 2.28)* |
| 65-79 | 60 | 3846.65 | 15.60 | 11.68 - 19.51 | 170 | 15720.01 | 10.81 | 9.20 - 12.43 | 1.44 (1.07 - 1.94)* | 1.25 (0.92 - 1.71) |
| ≥ 80 | 12 | 868.91 | 13.81 | 6.05 - 21.57 | 38 | 3544.48 | 10.72 | 7.33 - 14.11 | 1.28 (0.67 - 2.46) | 1.31 (0.64 - 2.68) |
| Sexb | ||||||||||
| Men | 17 | 1142.92 | 14.87 | 7.86 - 21.89 | 48 | 4719.56 | 10.17 | 7.31 - 13.03 | 1.46 (0.84 - 2.54) | 1.09 (0.60 - 1.96) |
| Women | 97 | 6652.69 | 14.58 | 11.70 - 17.46 | 263 | 27247.33 | 9.65 | 8.49 - 10.81 | 1.51 (1.20 - 1.91)** | 1.40 (1.09 - 1.79)** |
| Total | 114 | 7795.61 | 14.62 | 11.96 - 17.29 | 311 | 31966.89 | 9.73 | 8.65 - 10.80 | 1.50 (1.21 - 1.86)*** | 1.35 (1.07 - 1.69)* |
*p <0.05,**p <0.01, ***p <0.001.
HR, hazard ratio; ID, incidence density (per 1000 patient-years); CI, confidence interval.
1Based on the Poisson assumption.
aAdjusted for sex, age, monthly income, region, urbanization level, hypertension, hyperlipidemia, diabetes, cirrhosis, spinal cord injury, hormone replacement, and clofibrate.
bAdjusted for age, monthly income, region, urbanization level, hypertension, hyperlipidemia, diabetes, cirrhosis, spinal cord injury, hormone replacement, and clofibrate.